JMT-103
- Generic Name
- JMT-103
The Efficacy and Safety of Narlumosbart in Combination with Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- NSCLCStereotactic Body Radiation Therapy (SBRT)Immunotherapy
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 27
- Registration Number
- NCT06738160
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
Phase 3
Not yet recruiting
- Conditions
- Multiple MyelomaBone Diseases
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 478
- Registration Number
- NCT06314698
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
Phase 3
Not yet recruiting
- Conditions
- Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 1360
- Registration Number
- NCT06221072
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Phase 3
Not yet recruiting
- Conditions
- Giant Cell Tumor of Bone
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT05813665
- Locations
- 🇨🇳
Beijing Ji Shui Tan Hospital, Beijing, Beijing, China
Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
Phase 2
- Conditions
- Glucocorticoid Induced Osteoporosis
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT05397938
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05278338
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, Jilin, China
A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04198480
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath